Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677481 (urinary frequency)
 1,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Among all tissue examinations, 8.6% were on male urogenital organs, of which 2.9% were for carcinoma of the prostate. Biopsies of the prostate comprised a large percentage of all male urogenital biopsies. Since the specimens examined by various pathological laboratories in Tehran were received from all over the country, comparison of these statistics is significant. 2. Male urogenital tumors comprised 6.7% of male biopsies, of which 2.7% were for tumors of the prostate. 3. Male urogenital cancers comprised 2.3% of biopsies examined, of which only four were prostatic carconomas. Carcinoma of the prostate was the rarest cancer of the male urogenital organs in Iran. 4. We found 933 cases of cancer of male urogenital organs in 31 years. This comprised 6% of all male cancers, of which only 0.33% were carcinoma of the prostate. 5. Bladder carcinomas were the commonest and prostate carcinomas the rarest among males. 6. We found that 97% of prostate tumors were benign and 3% were malignant. Prostatic carcinoma was four times more prevalent among high income patients than among low income patients. 7. Benign tumors were most common in the 40 to 70 age groups, whereas the peak incidence for carcinoma of this organ was 50 to 70 years of age. 8. No particular clinical symptoms were found. Most patients reported pollakiuria, dysuria or urinary retention. 9. The initial growth site of tumors in the few cases that we were able to study was in the cortex region, especially from the posterior lobe. 10. Histological types of tumor found did not differ from other figures reported. We found no sarcomas. 11. No systematic study of asymptomatic nodules of carcinoma of the prostate has been made and we have never found any signs of such solitary nodules. This may be due to the low average age and the rarity of malignancy of the prostate in Iran. 12. The frequency of death in Iran due to carcinoma of the prostate is impossible to state since death certificates, in the majority of cases, specify secondary symptoms of the disease and not the original disease. 13. The incidence of prostatic carcinoma in the provice of Fars was five times greater and in Isfahan four times greater than in the province of Tehran. However, the figures for Tehran were compiled over the last 31 years, whereas the figures for Isfahan and Shiraz are only for the last ten years, and comparison of these three sets of figures may not be accurate. 14. Carcinoma of the prostate is not as common in Iran as it is in Europe and America. It is rather rare in Iran and compares favorably with figures for the Near Eastern and Far Eastern countries. The Middle Eastern countries of Lebanon, Israel and Afghanistan are very similar in incidence to Iran. In other countries in our region, the incidence is 1.8%.
 ...
PMID:Prostatic tumors in Iran. 115 17

A 63-year-old man was admitted with the complaints of macrohematuria, sense of residual urine and urinary frequency. Physical examination revealed an enlarged hard prostate and left scrotal mass. The pathological diagnosis of the needle biopsy specimen of the prostate showed undifferentiated adenocarcinoma. The patient underwent bilateral orchiectomy for hormone therapy of prostatic carcinoma and treatment of suspected left testicular tumor. The histology of testicular tumor revealed metastasis from carcinoma of the prostate. Metastasis of the testis from prostatic carcinoma is rare in spite of the high incidence of the primary tumor. Clinical findings on testicular metastasis from carcinoma of the prostate obtained in 62 cases reported in available literature are reviewed and discussed in detail.
 ...
PMID:[Prostatic carcinoma with metastasis to the testicle: a case report]. 372 49

The acute morbidity of high dose radiation therapy for carcinoma of the prostate in a group of 169 patients treated between February 1993 and April 1994 was examined. Morbidity was determined at the start of therapy, then weekly during therapy and at 1, 2, 3, 6 and 12 months after therapy. Morbidity was examined from the view of the treating doctor and the patients. Morbidity was found to peak at the end of the treatment. From the radiation oncologist's perspective, 80-85% of patients experienced significant bladder and bowel morbidity. The level of acute morbidity was acceptable and there was only one patient that was admitted to hospital for symptomatic control of his acute reaction. Recovery was practically complete after 3 months for both bladder and bowel morbidity. Fifty per cent of patients experienced dysuria, 75% perianal discomfort and 87% frequency at the end of the treatment. Most of the individual factors recovered following radiation but urinary frequency and perianal discomfort were the most persistent problems.
 ...
PMID:Acute morbidity of radiation therapy for prostate carcinoma. 868 46

Malakoplakia is an unusual chronic inflammatory disease that was first discovered in the urinary bladder but has subsequently been described in other sites. Characteristic gross and microscopic features of the lesions have been well described. The diagnosis of this tumor-like lesion can only be established by pathologic examination of the involved tissue. A case of prostatic malakoplakia with characteristic gross and microscopic features is reported in a 59-year-old man who presented with urinary frequency and a diminished urinary stream. Clinically the condition mimicked carcinoma of the prostate gland and the patient underwent a radical retropubic prostatectomy. Postoperative recovery was uneventful. The clinical and pathological findings, differential diagnosis and pertinent literature are reviewed. Preoperative needle biopsy or intraoperative frozen section for tissue diagnosis is recommended to avoid unnecessary radical surgery for this type of tumor-like lesion.
 ...
PMID:Malakoplakia of the prostate: a case report. 950 65

One of the options for treating localized carcinoma of the prostate includes the implantation of radioactive seeds under ultrasound guidance (brachytherapy). A community hospital-based prostate brachytherapy program was started in 1992. The overall survival and disease-free survival figures for the initial 100 patients treated in this program seem comparable to patients treated by radical prostatectomy or brachytherapy in larger series. The main side effects of brachytherapy included nocturia, daytime urinary frequency, dysuria, and proctitis. These side effects were transient and decreased to less than 10% by 12 to 24 months following implantation. Prostate brachytherapy can be effectively and safely provided in a community hospital setting.
 ...
PMID:Prostate brachytherapy--the community hospital experience. 1105 85

Ductal adenocarcinoma of the prostate was initially described in 1967 by Melicow and Patcher. It was given the erroneous name endometrioid carcinoma, however, further studies confirmed the prostatic origin of this tumor. Currently DAP is classified as a histological variant of prostatic carcinoma. Compared with "classic" acinar carcinoma of the prostate, DAP is a rare histological finding. It's prevalence in prostatectomy and biopsy specimens varies from less than 1% for pure ductal adenocarcinoma up to 5% for mixed DAP. Because of its typical periurethral location, the tumor usually manifests itself clinically with urinary obstruction, urinary urgency, urinary frequency and hematuria. DAP is associated with more aggressive natural history and worse prognosis than pure AA - patients presented at more advanced stage, with poorly differentiated and distant disease. DAP has a tendency to spread to regional lymph nodes, axial skeleton, and visceral organs. We report a case of a 90-year old man who presented to our clinic with acute urinary retention and gross hematuria. He underwent suprapubic transvesical adenomectomy to diminish the urinary obstruction. The pathological examination of the specimens revealed a dominant focus of DAP, which was located near the intraprostatic urethra and a coexisting, smaller component of "classic" acinar adenocarcinoma.
...
PMID:An incidentally diagnosed prostatic ductal adenocarcinoma. 2457 20

Urinary toxicity is common after low-dose-rate (LDR) brachytherapy, and the resolution of urinary toxicity is a concern. In particular, urinary frequency is the most common adverse event among the urinary toxicities. We have previously reported that approximately 70% of patients experience urinary frequency during the first 6 months after seed implantation. Most urinary adverse events were classified as Grade 1, and Grade 2 or higher adverse events were rare. The incidence of urinary retention was approximately 2-4%. A high International Prostate Symptom Score before seed implantation was an independent predictor of acute urinary toxicity of Grade 2 or higher. Several previous reports from the United States also supported this trend. In Japan, LDR brachytherapy was legally approved in 2003. A nationwide prospective cohort study entitled Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation was initiated in July 2005. It is an important issue to limit urinary toxicities in patients who undergo LDR brachytherapy.
 ...
PMID:Urethral toxicity after LDR brachytherapy: experience in Japan. 2545 83